Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 1/2 2Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 68Recurrence 17Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Renal Insufficiency 2Plasmacytoma 2Myeloproliferative Disorders 2Chromosome 17 deletion 2Amyloidosis 2Thrombocytosis 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8daratumumab 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × pomalidomide × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT04895917 2025-02-20

DarPAL

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Terminated
27 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06342466 2024-12-30

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Peking University People's Hospital

Phase 2 Recruiting
40 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown
46 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01510613 2018-03-12

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡